Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ABBV-382 in People Living With HIV-1
NCT04554966Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ABBV-382 in human immunodeficiency virus type 1 infection (HIV-1) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Incidence of Study Drug-Related Grade 3 or Higher Adverse Events, Maximum Observed Serum Concentration and 7 more. Started Apr 2021; status: completed.
02
Drugs
ABBV-382
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04554966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04554966.